Clinical Trial Update: Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating memantine as an add-on to dopamine modulation to improve negative symptoms in first-episode psychosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Bjorn H. Ebdrup | Conditions: Psychosis, Negative Symptoms With Primary Psychotic Disorder | Phase 1 | Status: RECRUITING